
Opinion|Videos|July 12, 2024
Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC
Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.
Advertisement
Episodes in this series

- How might the advent of subcutaneous amivantamab, currently being studied in the
PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose?
- How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference
2
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
3
SNO 2026 Roundup: What Longer Follow-Up Means for Targeted Glioma Care
4
Overton FDA Nomination Withdrawn: What It Means for Pharmacists
5


